Literature DB >> 24831275

Pharmacologic biomarkers in the development of stratified cancer medicine.

William Douglas Figg1, David R Newell1.   

Abstract

Clinical pharmacologic research plays a vital role in cancer drug development. In recent years, biomarker studies have become integral to this process, specifically the use of pharmacologic biomarkers in the development of targeted therapies and their translation to clinical practice. In this overview, we discuss the validation of pharmacodynamics (PD) biomarkers and highlight the circulating tumor DNA as a promising cancer biomarker to illustrate how PD biomarkers can be powerful tools for guiding treatment strategies. We provide insights into PD biomarker approaches for future development of novel therapies and their role in cancer medicine. See all articles in this CCR focus section, "Progress in pharmacodynamic endpoints." ©2014 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24831275      PMCID： PMC4024707          DOI： 10.1158/1078-0432.CCR-14-0511

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  25 in total

1.  Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer.

Authors:  Sandra Misale; Rona Yaeger; Sebastijan Hobor; Elisa Scala; Manickam Janakiraman; David Liska; Emanuele Valtorta; Roberta Schiavo; Michela Buscarino; Giulia Siravegna; Katia Bencardino; Andrea Cercek; Chin-Tung Chen; Silvio Veronese; Carlo Zanon; Andrea Sartore-Bianchi; Marcello Gambacorta; Margherita Gallicchio; Efsevia Vakiani; Valentina Boscaro; Enzo Medico; Martin Weiser; Salvatore Siena; Federica Di Nicolantonio; David Solit; Alberto Bardelli
Journal:  Nature       Date:  2012-06-28       Impact factor: 49.962

Review 2.  Process map proposal for the validation of genomic biomarkers.

Authors:  Federico Goodsaid; Felix Frueh
Journal:  Pharmacogenomics       Date:  2006-07       Impact factor: 2.533

3.  Fit-for-purpose method development and validation for successful biomarker measurement.

Authors:  Jean W Lee; Viswanath Devanarayan; Yu Chen Barrett; Russell Weiner; John Allinson; Scott Fountain; Stephen Keller; Ira Weinryb; Marie Green; Larry Duan; James A Rogers; Robert Millham; Peter J O'Brien; Jeff Sailstad; Masood Khan; Chad Ray; John A Wagner
Journal:  Pharm Res       Date:  2006-01-12       Impact factor: 4.200

4.  DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells.

Authors:  S Jahr; H Hentze; S Englisch; D Hardt; F O Fackelmayer; R D Hesch; R Knippers
Journal:  Cancer Res       Date:  2001-02-15       Impact factor: 12.701

Review 5.  Genome-wide association study: a useful tool to identify common genetic variants associated with drug toxicity and efficacy in cancer pharmacogenomics.

Authors:  Siew-Kee Low; Atsushi Takahashi; Taisei Mushiroda; Michiaki Kubo
Journal:  Clin Cancer Res       Date:  2014-05-15       Impact factor: 12.531

6.  Detection of circulating tumor DNA in early- and late-stage human malignancies.

Authors:  Chetan Bettegowda; Mark Sausen; Rebecca J Leary; Isaac Kinde; Yuxuan Wang; Nishant Agrawal; Bjarne R Bartlett; Hao Wang; Brandon Luber; Rhoda M Alani; Emmanuel S Antonarakis; Nilofer S Azad; Alberto Bardelli; Henry Brem; John L Cameron; Clarence C Lee; Leslie A Fecher; Gary L Gallia; Peter Gibbs; Dung Le; Robert L Giuntoli; Michael Goggins; Michael D Hogarty; Matthias Holdhoff; Seung-Mo Hong; Yuchen Jiao; Hartmut H Juhl; Jenny J Kim; Giulia Siravegna; Daniel A Laheru; Calogero Lauricella; Michael Lim; Evan J Lipson; Suely Kazue Nagahashi Marie; George J Netto; Kelly S Oliner; Alessandro Olivi; Louise Olsson; Gregory J Riggins; Andrea Sartore-Bianchi; Kerstin Schmidt; le-Ming Shih; Sueli Mieko Oba-Shinjo; Salvatore Siena; Dan Theodorescu; Jeanne Tie; Timothy T Harkins; Silvio Veronese; Tian-Li Wang; Jon D Weingart; Christopher L Wolfgang; Laura D Wood; Dongmei Xing; Ralph H Hruban; Jian Wu; Peter J Allen; C Max Schmidt; Michael A Choti; Victor E Velculescu; Kenneth W Kinzler; Bert Vogelstein; Nickolas Papadopoulos; Luis A Diaz
Journal:  Sci Transl Med       Date:  2014-02-19       Impact factor: 17.956

Review 7.  Rapid translation of circulating tumor cell biomarkers into clinical practice: technology development, clinical needs and regulatory requirements.

Authors:  Jonathan D King; Benjamin P Casavant; Joshua M Lang
Journal:  Lab Chip       Date:  2013-11-05       Impact factor: 6.799

8.  Detection rate and prognostic value of circulating tumor cells and circulating tumor DNA in metastatic uveal melanoma.

Authors:  François-Clément Bidard; Jordan Madic; Pascale Mariani; Sophie Piperno-Neumann; Aurore Rampanou; Vincent Servois; Nathalie Cassoux; Laurence Desjardins; Maud Milder; Isabelle Vaucher; Jean-Yves Pierga; Ronald Lebofsky; Marc-Henri Stern; Olivier Lantz
Journal:  Int J Cancer       Date:  2013-09-03       Impact factor: 7.396

Review 9.  Circulating tumor cells: a multifunctional biomarker.

Authors:  Timothy A Yap; David Lorente; Aurelius Omlin; David Olmos; Johann S de Bono
Journal:  Clin Cancer Res       Date:  2014-05-15       Impact factor: 12.531

Review 10.  Overview of biomarkers and surrogate endpoints in drug development.

Authors:  John A Wagner
Journal:  Dis Markers       Date:  2002       Impact factor: 3.434
View more
  2 in total

1.  Shear induced carboplatin binding within the cavity of a phospholipid mimic for increased anticancer efficacy.

Authors:  Jingxin Mo; Paul K Eggers; Xianjue Chen; Muhammad Rizwan Hussain Ahamed; Thomas Becker; Lee Yong Lim; Colin L Raston
Journal:  Sci Rep       Date:  2015-05-22       Impact factor: 4.379

2.  Shortwave infrared emitting multicolored nanoprobes for biomarker-specific cancer imaging in vivo.

Authors:  Harini Kantamneni; Shravani Barkund; Michael Donzanti; Daniel Martin; Xinyu Zhao; Shuqing He; Richard E Riman; Mei Chee Tan; Mark C Pierce; Charles M Roth; Vidya Ganapathy; Prabhas V Moghe
Journal:  BMC Cancer       Date:  2020-11-10       Impact factor: 4.430
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.